| Catalog Number |
PR1374640706 |
| CAS |
1374640-70-6 |
| Description |
Rociletinib has been used in trials studying the treatment and prevention of Nonsmall Cell Lung Cancer, Non-small Cell Lung Cancer, and Locally Advanced or Metastatic Non-small Cell Lung Cancer. |
| Synonyms |
CO-1686 |
| IUPAC Name |
N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide |
| Molecular Weight |
555.6 |
| Molecular Formula |
C27H28F3N7O3 |
| InChI |
HUFOZJXAKZVRNJ-UHFFFAOYSA-N |
| InChI Key |
InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35) |
| Drug Categories |
Acids, Acyclic; Acrylates; Amides; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors; Protein Kinase Inhibitors |
| Drug Interactions |
Ambroxol-The risk or severity of methemoglobinemia can be increased when Rociletinib is combined with Ambroxol.
Articaine-The risk or severity of methemoglobinemia can be increased when Rociletinib is combined with Articaine.
Benzocaine-The risk or severity of methemoglobinemia can be increased when Rociletinib is combined with Benzocaine.
Benzyl alcohol-The risk or severity of methemoglobinemia can be increased when Rociletinib is combined with Benzyl alcohol.
Bupivacaine-The risk or severity of methemoglobinemia can be increased when Rociletinib is combined with Bupivacaine. |
| Isomeric SMILES |
CC(=O)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F)OC |
| Type |
Small Molecule |
| Therapeutic Category |
Anticancer |
It should be noted that our service is only used for research, not for clinical use.
